DIRE vs Asthma Control T
Price, ratings, monetisation and update history for both apps, side by side — with what reviewers say about each.
DIRE
This tool assists clinicians in evaluating the risk and potential success of prescribing opioids for chronic pain. It uses a scoring system based on seven factors to guide decision-making, but does not replace professional judgment.
- Opioid prescribing risk assessment
- Seven-factor scoring system
- Chronic non-malignant pain focus
- Decision-making aid for clinicians
- Risk vs. success prediction
Read full descriptionHide full description
The DIRE Score is a tool that can be used to aid clinicians in their decision-making process when considering prescribing opioids for chronic non-malignant pain. Using the DIRE Score, the clinician rates seven factors each on a scale of 1, 2 or 3 with 1 being the least favorable or highest risk for prescribing opioids and 3 being the most compelling or lowest risk for prescribing. The seven DIRE factors are: Diagnosis, Intractability, Risk (there are four risk factors—psychological and chemical health, patient reliability and social support/life roles) and Efficacy. Adding the scores for these seven factors gives a total of 7 – 21. A score of 7-13 was predictive of a low probability of success when prescribing opioids; whereas a score of 14-21 was more likely to be associated with a successful prescribing process and outcome. The DIRE Score does not take into account medical risk factors for opioid prescribing such as comorbid medical conditions (chronic obstructive lung disease, sleep apnea, concomitant use of benzodiazepines, etc.). The clinician should understand that active use of illicit drugs, drug diversion and other aberrant behaviors is incompatible with ongoing opioid prescribing no matter what the DIRE Score may be. The DIRE Score is not meant to be a substitute for sound clinical judgment in the context of any individual patient. This App is meant for informational use only, and is not intended to aid in the diagnosis, treatment or prevention of disease. Decisions about prescribing are solely the responsibility of the licensed prescriber.
Asthma Control T
Read full descriptionHide full description
The Asthma Control Test (ACT) is a validated, reliable, and internationally recognized digital tool that allows users to quickly and easily assess the level of control of their asthma symptoms. It is designed for people who have already been diagnosed with asthma and helps both patients and their healthcare providers better manage the condition. **Available in 6 languages: English, Spanish, French, Italian, Portuguese, German** * Key Features 1. Personalized Questionnaires - Children (4–11 years): 7 questions, approximately 5 minutes to complete. - Adults (≥12 years): 5 questions, approximately 1 minute to complete. Both questionnaires are short, easy to use, and tailored to each age group. 2. Scores are presented using a traffic light color scale: Red: Poorly controlled asthma Yellow: Partially controlled asthma Green: Well-controlled asthma 3. History and Follow-up Records results by name, with date and score. Option to share results with healthcare providers. Allows users to save and review previous results to track asthma control over time. 4. The app allows you to set monthly reminders to repeat the test and maintain consistent monitoring. Disclaimer The Asthma Control Test (ACT) is intended only for individuals who have already been diagnosed with asthma by a healthcare professional. The ACT does not replace professional medical advice, diagnosis, care, treatment, or monitoring. If you have concerns about your health, experience new or worsening symptoms, or have questions regarding your condition, you should always seek guidance from a qualified healthcare professional.
Screenshots
Verdict
The clearest difference is ads: DIRE at none against Asthma Control T's shown. DIRE also leads on iOS requirement (12.0 vs 15.0). Asthma Control T's advantage is update cadence (every 3 months vs every 51 months). On price, in-app purchases and device support there is nothing between them.
Scored on Price · Rating · Positive reviews · Number of ratings · Update frequency · Ads · In-app purchases · Monetization · Best chart rank · Devices · Requires iOS
Both are free to download. Neither carries in-app purchases, so what you see is what you pay.
DIRE ships an update every 51 months, Asthma Control T every 3 months. The most recent releases landed on November 2, 2026 and October 30, 2026 respectively.
| Parameter | DIRE | Asthma Control T |
|---|---|---|
| Price | Free | Free |
| Rating | 5.0 (1 ratings) — better | — |
| Positive reviews | 100.0% of reviews | — |
| Number of ratings | 1 — better | — |
| Update frequency | Every 51 months | Every 3 months — better |
| Ads | No — better | Yes |
| In-app purchases | No | No |
| Monetization | Free | — |
| Devices | iPhone, iPad, iPod | iPhone, iPad, iPod |
| Requires iOS | 12.0 — better | 15.0 |
| Further details — not scored | ||
| Size | 8 MB | 144 MB |
| Age rating | 17+ | +4 |
| Developer | Riemenrade Studios LLC | Gerson Rodriguez |
In-app purchases
DIRE
No in-app purchases
Asthma Control T
No in-app purchases
Questions
Is DIRE free?
Is Asthma Control T free?
Do DIRE or Asthma Control T have ads?
Which is updated more often, DIRE or Asthma Control T?
Other comparisons















